Standout Papers

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ej... 2003 2026 2010 2018 2.0k
  1. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial (2003)
    Salim Yusuf, Marc A. Pfeffer et al. The Lancet
  2. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial (2003)
    John J.V. McMurray, Jan Östergren et al. The Lancet
  3. Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events (2003)
    Christopher B. Granger Archives of Internal Medicine
  4. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (2003)
    Marc A. Pfeffer, Karl Swedberg et al. The Lancet
  5. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2018)
    Sana M. Al‐Khatib, William G. Stevenson et al. Journal of the American College of Cardiology
  6. A Validated Prediction Model for All Forms of Acute Coronary Syndrome (2004)
    Kim A. Eagle, Michael J. Lim et al. JAMA
  7. Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety (2001)
    Jack Hirsh, Stephen G. Shaughnessy et al. CHEST Journal
  8. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial (2003)
    Christopher B. Granger, John J.V. McMurray et al. The Lancet
  9. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) (2006)
    Keith A.A. Fox, Omar Dabbous et al. BMJ
  10. Embolic strokes of undetermined source: the case for a new clinical construct (2014)
    Robert G. Hart, Hans‐Christoph Diener et al. The Lancet Neurology
  11. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease (2016)
    Glenn N. Levine, Eric Bates et al. Journal of the American College of Cardiology
  12. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves (2013)
    John W. Eikelboom, Stuart J. Connolly et al. New England Journal of Medicine
  13. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery (2016)
    Glenn N. Levine, Eric Bates et al. Circulation
  14. Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia (1996)
    E. Magnus Ohman, Paul W. Armstrong et al. New England Journal of Medicine
  15. Heparin and Low-Molecular-Weight Heparin (1998)
    Jack Hirsh, Robert Raschke et al. CHEST Journal
  16. Predictors of mortality and morbidity in patients with chronic heart failure (2005)
    Stuart Pocock, Duolao Wang et al. European Heart Journal
  17. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure (2007)
    G. Michael Felker, Larry A. Allen et al. Journal of the American College of Cardiology
  18. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006)
    Hans L. Hillege, Dorothea Nitsch et al. Circulation
  19. Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006 (2007)
    Keith A.A. Fox, Philippe Gabríel Steg et al. JAMA
  20. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients (2005)
    Scott D. Solomon, Nagesh S. Anavekar et al. Circulation
  21. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes (2009)
    Shamir R. Mehta, Christopher B. Granger et al. New England Journal of Medicine
  22. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary (2017)
    Sana M. Al‐Khatib, William G. Stevenson et al. Journal of the American College of Cardiology
  23. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2017)
    Sana M. Al‐Khatib, William G. Stevenson et al. Circulation
  24. Fundamentals of Clinical Trials (2015)
    Lawrence M. Friedman, Curt D. Furberg et al. CERN Document Server (European Organization for Nuclear Research)
  25. Relationship Between Infarct Size and Outcomes Following Primary PCI (2016)
    Gregg W. Stone, Harry P. Selker et al. Journal of the American College of Cardiology
  26. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial (2012)
    Stefan H. Hohnloser, Ziad Hijazi et al. European Heart Journal
  27. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary (2017)
    Sana M. Al‐Khatib, William G. Stevenson et al. Heart Rhythm
  28. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (2017)
    Sana M. Al‐Khatib, William G. Stevenson et al. Heart Rhythm
  29. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study (2016)
    Ziad Hijazi, Jonas Oldgren et al. The Lancet
  30. Association of Bystander and First-Responder Intervention With Survival After Out-of-Hospital Cardiac Arrest in North Carolina, 2010-2013 (2015)
    Carolina Malta Hansen, Kristian Kragholm et al. JAMA
  31. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation (2016)
    Ziad Hijazi, Johan Lindbäck et al. European Heart Journal
  32. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials (2017)
    Suzanne de Waha, Manesh R. Patel et al. European Heart Journal
  33. Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum (2018)
    Lars H. Lund, Brian Claggett et al. European Journal of Heart Failure
  34. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary (2017)
    Sana M. Al‐Khatib, William G. Stevenson et al. Circulation
  35. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study (2018)
    Mintu P. Turakhia, Manisha Desai et al. American Heart Journal
  36. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials (2023)
    William F. McIntyre, Alexander P. Benz et al. Circulation

Immediate Impact

2 from Science/Nature 101 standout
Sub-graph 1 of 18

Citing Papers

Blinded, randomized trial of sonographer versus AI cardiac function assessment
2023 StandoutNature
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2018 Standout
3 intermediate papers

Works of Christopher B. Granger being referenced

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
2017 Standout
Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved
2013
and 5 more

Author Peers

Author Last Decade Papers Cites
Christopher B. Granger 48225 13453 9696 833 62.0k
Harvey D. White 43840 21177 13505 705 56.2k
Eugene Braunwald 41820 18050 12184 444 56.1k
Bernard J. Gersh 60179 18709 13371 1.1k 74.3k
Elliott M. Antman 46958 16447 10589 515 57.8k
Keith A.A. Fox 46242 15084 10760 808 57.9k
Eric D. Peterson 45772 20943 7784 1.2k 77.4k
Philippe Gabríel Steg 54884 29325 9926 1.1k 74.8k
Allan S. Jaffe 37677 13311 13469 609 49.8k
David A. Morrow 28608 12434 8970 579 42.3k
Frans Van de Werf 30131 12126 9820 746 39.2k

All Works

Loading papers...

Rankless by CCL
2026